Literature DB >> 16630073

Production and clearance of cyclobutane dipyrimidine dimers in UV-irradiated skin pretreated with 1% pimecrolimus or 0.1% triamcinolone acetonide creams in normal and atopic patients.

Laurence Doelker1, Christian Tran, Angelos Gkomouzas, Denise Grand, Olivier Sorg, Jean-Hilaire Saurat, Jann Lübbe.   

Abstract

BACKGROUND: Ultraviolet (UV)-induced pyrimidine dimers are an early step in skin carcinogenesis, which is accelerated in the setting of long-term immunosuppression with systemic calcineurin inhibitors. It is not known whether topical application of calcineurin inhibitors exposes to a similar risk.
OBJECTIVE: To assess the formation and clearance of UV-induced dipyrimidine dimers in human epidermis treated with topical pimecrolimus as compared to topical steroid, vehicle and untreated control.
METHODS: Pretreated buttock skin of 20 human volunteers with (10) or without (10) atopic dermatitis was exposed to two minimal erythema doses (MED) of simulated solar radiation. DNA was extracted from epidermis 1 and 24 h postirradiation. Pyrimidine dimers were visualized by immuno slot blots and quantified by chemoluminescence image analysis.
RESULTS: One-hour postirradiation, pimecrolimus-treated epidermis contains less DNA damage as compared to untreated control, but there were no statistically significant differences between pimecrolimus, triamcinolone acetonide and vehicle. Dimer levels at 24 h postirradiation showed no significant differences between different treatments.
CONCLUSION: Treatment with pimecrolimus cream, triamcinolone acetonide cream and vehicle is not associated with increased epidermal DNA damage at 1 and 24 h post-UV exposure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16630073     DOI: 10.1111/j.0906-6705.2006.00413.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  5 in total

Review 1.  Topical calcineurin inhibitors in pediatric atopic dermatitis: a critical analysis of current issues.

Authors:  Seth J Orlow
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

Review 2.  Topical pimecrolimus: a review of its use in the management of pediatric atopic dermatitis.

Authors:  Lily P H Yang; Monique P Curran
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

Review 3.  The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy.

Authors:  Johannes Ring; Matthias Möhrenschlager; Verena Henkel
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 4.  Photocarcinogenicity of selected topically applied dermatological drugs: calcineurin inhibitors, corticosteroids, and vitamin D analogs.

Authors:  Catharina M Lerche; Hans Christian Wulf
Journal:  Dermatol Reports       Date:  2010-09-14

5.  Pimecrolimus Is a Potent Inhibitor of Allergic Reactions to Hymenopteran Venom Extracts and Birch Pollen Allergen In Vitro.

Authors:  Petr Heneberg; Kamila Riegerová; Petr Kučera
Journal:  PLoS One       Date:  2015-11-12       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.